GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus

Impaired adipogenesis plays an important role in the development of obesity-associated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition. The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment...

Full description

Saved in:
Bibliographic Details
Published inCurrent diabetes reviews Vol. 17; no. 2; p. 169
Main Authors Al-Jaber, Hend, Al-Mansoori, Layla, Elrayess, Mohamed A
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2021
Subjects
Adipogenesis
Adipose Tissue
Diabetes Mellitus, Type 2 - drug therapy
Humans
Inflammation - drug therapy
Insulin Resistance
Obesity - complications
Obesity - drug therapy
therapeutic target
adipogenesis
type 2 diabetes
inflammation
insulin resistance
GATA-3
Online AccessGet more information

Cover

More Information
Summary:Impaired adipogenesis plays an important role in the development of obesity-associated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition. The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation is a crucial mediator of this process. Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA- 3, causing exacerbation of the inflammatory state associated with obesity. This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and amelioration of the immune response.
ISSN:1875-6417
DOI:10.2174/1573399816666200705210417